USPTO serial 86567126
COVANCE
Reviewed by CopyMark Law Group
Reg. 4897520Status 710
- Filing date
- Status date
- Registration date
- Feb 9, 2016
- Examiner
- SPARACINO, MARK V
- Law office
- —
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with COVANCE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
PRINCETON, NJ, US
Princeton, NJ, US
Princeton, NJ, US
Princeton, NJ, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
William M. Bryner
William M. Bryner Kilpatrick Townsend & Stockton LLP1100 Peachtree Street, Suite 2800Mailstop: IP Docketing - 22Atlanta, GA 30309Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Downloadable electronic publications, namely, books, pamphlets, articles, technical manuals, instructional and teaching materials, and reports in the fields of research and development of pharmaceutical, medical devices, biotechnology, and biochemicals | SECTION 8 - CANCELLED | — |
| 016 | Printed matter, namely, books, pamphlets, articles, technical manuals, instructional and teaching materials, and reports in the fields of research and development of pharmaceuticals, medical devices, biotechnology, and biochemicals | SECTION 8 - CANCELLED | — |
| 031 | [ Live animals; live laboratory animals ] | SECTION 8 - CANCELLED | — |
| 035 | Business consultancy services; business management consultancy and advisory services; consultancy and advisory services in the field of business strategy; marketing services; regulatory submission management, namely, assisting others in preparing and filing applications with governmental regulatory bodies for approval of new drugs and medical devices; economic forecasting and analysis; market research; business consulting services in the field of commercialization of pharmaceuticals, medical devices, biotechnology, and biochemicals; business management services, namely, forecasting drug supplies for clinical trials; business management services, namely, recruiting patients and volunteers for clinical trials; business administration of patient reimbursement programs; project management services for others for business purposes in the field of research and development of pharmaceuticals, medical devices, biotechnology, and biochemicals; database management; business information services; business data analysis; business advice and commercial information | SECTION 8 - CANCELLED | — |
| 036 | Providing a database featuring information and statistics about patient reimbursement and insurance coverage for pharmaceuticals and medical devices; financial administration of patient reimbursement programs | SECTION 8 - CANCELLED | — |
| 042 | Scientific research and development; pharmaceutical drug development and testing services; research and development of pharmaceuticals, medical devices, biotechnology, and biochemicals; medical and scientific research, namely, designing, organizing, conducting, monitoring, and managing clinical and non-clinical trials and studies on pharmaceuticals and medical devices for others; scientific consulting services for others in the field of clinical and non-clinical trials and studies on pharmaceuticals and medical devices; collection, calibration, analysis and reporting of medical and scientific research data in connection with clinical and non-clinical trials and studies on pharmaceuticals and medical devices; scientific laboratory services; scientific laboratory services, namely, formulating and bioprocessing pharmaceuticals; rental of laboratory apparatus and instruments; operating and maintaining a biorepository for medical and scientific research purposes; scientific research and analysis in the fields of bioinformatics, biomarkers, genomics, proteomics, genotyping, and genetic profiling; custom design and development of chemical reagents and biochemical assays; medical laboratory services in the field of pathology; testing of laboratory animals for scientific research purposes; computer hardware and software design; development, updating and maintenance of software and databases; design and development of software for use in conducting animal and biological research in non-clinical pharmaceutical and medical device and development studies; providing online computer databases in the fields of research and development of pharmaceuticals, medical devices, biotechnology, and biochemicals; data mining; providing a website featuring technology enabling users to remotely track, monitor, analyze, and generate reports with information and statistics from clinical and non-clinical trials and studies on pharmaceuticals and medical devices; food safety testing and consultation related thereto; scientific research and analysis in the fields of food safety, food packaging, and nutritional chemistry; scientific research and analysis in the field of pharmacology; advisory services in the field of pharmaceutical drug development, namely, selecting animal and biological research models for use in testing drugs; advisory services in the field of pharmaceutical drug development, namely, selecting biomarkers for use in testing drugs; lead candidate drug optimization services, namely, scientific research in the field of identifying compounds for drug development; providing medical and scientific information in the fields of biochemistry, pharmaceuticals and clinical trials; providing online non-downloadable software for tracking, monitoring, analyzing, generating and reporting information and statistics about patient reimbursement and insurance coverage for pharmaceuticals and medical devices | SECTION 8 - CANCELLED | — |
| 044 | Medical services in the fields of pathology, pharmacology, and immunology; medical and psychological counseling; providing medical information and advice in the fields of pathology, pharmacology, and immunology; collection, organization, analysis, and reporting of medical data in connection with clinical and non-clinical trials and studies on pharmaceuticals and medical devices | SECTION 8 - CANCELLED | — |
| 045 | Regulatory compliance consulting in the fields of pharmaceuticals and medical devices; regulatory compliance consulting in the field of obtaining government authorization to market pharmaceuticals and medical devices; regulatory compliance consulting in the field of food safety and nutritional labeling; providing information and advisory services about regulatory compliance in the fields of pharmaceuticals, medical devices, food safety, and nutritional labeling | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by LABCORP DRUG DEVELOPMENT INC.
- Other trademarks owned by Covance Inc.
- Other trademarks owned by Covance Inc.
- Other trademarks owned by Covance Inc.
- Other trademarks in Class 009
- Other trademarks in Class 016
- Other trademarks in Class 031
- Other trademarks in Class 035
- Other trademarks in Class 036
- Other trademarks in Class 042
- Other trademarks in Class 044
- Other trademarks in Class 045
- Similar marks named COVANCE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 21, 2026 | CAEX | CANCELLED SEC. 8 (10-YR)/EXPIRED SECTION 9 | — |
| Feb 9, 2025 | REM2 | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED | — |
| Sep 7, 2022 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Nov 4, 2021 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | — |
| Nov 4, 2021 | C15P | REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Nov 4, 2021 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jul 30, 2021 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Feb 9, 2021 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Sep 20, 2018 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 20, 2018 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Feb 9, 2016 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 24, 2015 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 24, 2015 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 4, 2015 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 16, 2015 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Oct 7, 2015 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 7, 2015 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 15, 2015 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 15, 2015 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 15, 2015 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 23, 2015 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 23, 2015 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 23, 2015 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 19, 2015 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 6, 2015 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Apr 6, 2015 | ALIE | ASSIGNED TO LIE | — |
| Mar 30, 2015 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Mar 26, 2015 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 20, 2015 | NWAP | NEW APPLICATION ENTERED | — |